# Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment

> **NCT01002547** · PHASE4 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 105 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** pioglitazone-placebo
- **DRUG:** pioglitazone
- **DIETARY_SUPPLEMENT:** Vitamin E
- **DRUG:** pioglitazone-placebo
- **DIETARY_SUPPLEMENT:** Vitamin E
- **DRUG:** Vitamin E-placebo

## Key facts

- **NCT ID:** NCT01002547
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-24
- **Primary completion:** 2016-09-30
- **Final completion:** 2016-12-31
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2018-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01002547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01002547, "Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01002547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*